Amyris Is Spending Way Too Much on Manufacturing Costs

Already reeling from the broader market correction, investors appear less willing to extend the benefit of the doubt to Amyris (NASDAQ: AMRS). The synthetic biology company reported fourth-quarter and full-year 2019 operating results that showed little progress where it matters most. Shares tumbled by more than 20% soon after the opening bell on a day when most of the market started off significantly higher.